Invitae Multi-Cancer + RNA Panel
Use
The Invitae Multi-Cancer + RNA Panel is used to analyze DNA for genes associated with adult-onset, nonsyndromic hereditary cancers across major organ systems. This includes cancers affecting the breast, gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, and sarcoma. The panel aims to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting multiple organ systems. It helps confirm a diagnosis, guide treatment and management, and facilitate testing and diagnosis for at-risk relatives.
Special Instructions
The test is specifically designed for heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. For assistance with ordering or specimen collection, contact client services or refer to the assay details provided online. RNA testing supports the interpretation of DNA variants but is not intended as a standalone diagnostic test.
Limitations
The test has >99% analytical sensitivity and specificity for sequence variants, with some limitations for large insertions, deletions, and structural rearrangements. Single-exon copy number events may not be analyzed due to inherent sequence properties or reduced data quality. The RNA test's sensitivity may be reduced for variants at certain splice sites and complex rearrangements. The test does not guarantee coverage of sequence changes in promoter, non-coding exons, and certain non-coding regions unless defined.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
purple-top EDTA tube